Bharat Biotech to start Phase-1 trials of COVID-19 intranasal vaccine in Feb-March

Besides Covaxin, BharatBiotech has been actively working on developing another vaccine, for which it tied up with Washington UniversitySchool of Medicine in St Louis for the novel "chimp-adenovirus" (Chimpanzee adenovirus), a single dose intranasal vaccine for COVID-19.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news